# EyePoint, CoreWeave, and Eos Energy Stocks Drop to 52-Week Lows

- URL: https://stocks.freetheai.org/news/eyepoint-coreweave-and-eos-energy-stocks-drop-to-52-week-lows-098617
- Published: 2026-10-20T02:39:48Z
- Category: company_news; sentiment: bearish; impact: high
- Symbols: [NASDAQ:EYPT](https://stocks.freetheai.org/symbols/NASDAQ-EYPT), [NASDAQ:CRWV](https://stocks.freetheai.org/symbols/NASDAQ-CRWV), [NASDAQ:EOSE](https://stocks.freetheai.org/symbols/NASDAQ-EOSE)
- Written by our AI from expert market sources across the web for FreeTheAI Stocks, built by Vibhek Soni
- How write-ups are made: https://stocks.freetheai.org/how-we-write
- Not financial advice: https://stocks.freetheai.org/disclaimer

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) plummeted 85% while CoreWeave, Inc. Class A (NASDAQ:CRWV) and Eos Energy Enterprises, Inc. (NASDAQ:EOSE) also touched 52-week lows on Monday. EyePoint experienced the sharpest decline after its leading experimental drug failed a pivotal clinical trial.

The drug, DURAVYU, failed to demonstrate non-inferiority against aflibercept in a late-stage study treating wet age-related macular degeneration. In response to the setback, EyePoint announced plans to lay off 53% of its workforce to reduce costs while refocusing capital on alternative studies. Meanwhile, CoreWeave faced price target reductions from analysts citing elevated financing costs, and Eos Energy fell after projecting 2026 revenue near the lower end of its target range.

Investors will track whether EyePoint can preserve liquidity as it advances DURAVYU for diabetic macular edema. Market participants will also monitor CoreWeave's funding costs for data center expansions and Eos Energy's timeline for reaching positive gross margins.

## Key points

- EyePoint Pharmaceuticals stock fell over 85% after DURAVYU failed a Phase 3 study for wet age-related macular degeneration.
- EyePoint is cutting 53% of its workforce to generate $30 million in annualized savings while refocusing on diabetic macular edema trials.
- CoreWeave stock hit a 52-week low of $59.25 as target price cuts reflected concerns about expensive debt and infrastructure costs.
- Eos Energy stock dropped after management signaled 2026 revenue would land in the lower half of its $300 million to $350 million target.

## Questions and answers

### Why did EyePoint stock crash 85%?

EyePoint stock crashed after its experimental drug DURAVYU failed to match aflibercept in vision protection during a Phase 3 study for wet age-related macular degeneration.

### How is EyePoint responding to the drug trial failure?

EyePoint is laying off 53% of its workforce to save $30 million annually and reallocating remaining cash to Phase 3 trials of DURAVYU for diabetic macular edema.

### Why did Eos Energy stock fall despite higher third-quarter revenue?

Eos Energy stock fell because management expects 2026 revenue to come in at the lower end of its $300 million to $350 million forecast range.